Myriad Total Revenue vs Current Deferred Revenue Analysis

MYGN Stock

USD 16.27 0.01 0.06%

Myriad Genetics financial indicator trend analysis is infinitely more than just investigating Myriad Genetics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Myriad Genetics is a good investment. Please check the relationship between Myriad Genetics Total Revenue and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Total Revenue vs Current Deferred Revenue

Total Revenue vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Myriad Genetics Total Revenue account and Current Deferred Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Myriad Genetics' Total Revenue and Current Deferred Revenue is -0.72. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Myriad Genetics, assuming nothing else is changed. The correlation between historical values of Myriad Genetics' Total Revenue and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Myriad Genetics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Revenue i.e., Myriad Genetics' Total Revenue and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.72

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Total Revenue

Total revenue comprises all receipts Myriad Genetics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Myriad Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Myriad Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.At this time, Myriad Genetics' Tax Provision is very stable compared to the past year. As of the 29th of November 2024, Issuance Of Capital Stock is likely to grow to about 123.5 M, while Selling General Administrative is likely to drop about 468.6 M.

	2021	2022	2023	2024 (projected)
Total Revenue	690.6M	678.4M	753.2M	414.1M
Depreciation And Amortization	62.8M	55.9M	61.9M	65.0M

Total Revenue Depreciation And Amortization

Myriad Genetics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Short Term Investments	Common Stock	Current Deferred Revenue	Inventory	Good Will
Total Assets		0.66	0.58	0.71	0.94	0.37	0.14	-0.15	0.88	0.59	0.86	-0.61	-0.08	0.42	0.77	-0.17	0.67	0.8	0.24	0.39	0.86	-0.27	0.58	-0.54	0.67	0.85
Short Long Term Debt Total	0.66		0.56	0.37	0.55	0.37	0.37	-0.28	0.49	0.18	0.59	-0.28	-0.06	0.44	0.67	0.11	0.54	0.68	0.23	0.32	0.56	-0.13	0.5	-0.5	0.48	0.54
Other Current Liab	0.58	0.56		0.9	0.4	0.63	0.14	-0.62	0.49	0.61	0.68	-0.17	-0.1	0.2	0.72	-0.16	0.73	0.83	0.09	0.02	0.46	-0.45	0.34	-0.33	0.41	0.58
Total Current Liabilities	0.71	0.37	0.9		0.56	0.65	0.11	-0.55	0.64	0.68	0.8	-0.35	-0.16	0.21	0.75	-0.21	0.78	0.86	0.04	0.0	0.55	-0.49	0.37	-0.37	0.48	0.73
Total Stockholder Equity	0.94	0.55	0.4	0.56		0.27	0.04	-0.02	0.91	0.58	0.73	-0.51	0.11	0.58	0.58	-0.17	0.62	0.6	0.41	0.46	0.9	-0.06	0.69	-0.66	0.78	0.72
Property Plant And Equipment Net	0.37	0.37	0.63	0.65	0.27		0.32	-0.94	0.46	0.35	0.61	0.22	-0.27	0.23	0.56	-0.15	0.88	0.6	-0.16	-0.37	0.26	-0.52	0.32	-0.36	0.31	0.49
Net Debt	0.14	0.37	0.14	0.11	0.04	0.32		-0.26	0.24	-0.42	0.38	-0.14	-0.5	-0.1	0.56	-0.06	0.24	0.32	-0.46	-0.13	0.23	-0.38	-0.15	-0.05	-0.06	0.41
Retained Earnings	-0.15	-0.28	-0.62	-0.55	-0.02	-0.94	-0.26		-0.2	-0.28	-0.42	-0.34	0.24	-0.16	-0.44	0.04	-0.77	-0.49	0.19	0.47	-0.06	0.48	-0.24	0.25	-0.16	-0.31
Accounts Payable	0.88	0.49	0.49	0.64	0.91	0.46	0.24	-0.2		0.53	0.81	-0.36	-0.13	0.41	0.65	-0.29	0.7	0.63	0.14	0.27	0.9	-0.33	0.52	-0.56	0.66	0.8
Cash	0.59	0.18	0.61	0.68	0.58	0.35	-0.42	-0.28	0.53		0.44	-0.12	0.31	0.32	0.35	-0.16	0.55	0.48	0.44	-0.02	0.4	-0.09	0.45	-0.23	0.4	0.35
Non Current Assets Total	0.86	0.59	0.68	0.8	0.73	0.61	0.38	-0.42	0.81	0.44		-0.57	-0.43	0.15	0.93	-0.24	0.79	0.93	-0.16	0.24	0.7	-0.65	0.29	-0.4	0.5	0.98
Non Currrent Assets Other	-0.61	-0.28	-0.17	-0.35	-0.51	0.22	-0.14	-0.34	-0.36	-0.12	-0.57		0.23	0.06	-0.57	0.07	-0.09	-0.57	0.03	-0.59	-0.47	0.24	-0.04	0.11	-0.24	-0.66
Cash And Short Term Investments	-0.08	-0.06	-0.1	-0.16	0.11	-0.27	-0.5	0.24	-0.13	0.31	-0.43	0.23		0.62	-0.41	0.15	-0.08	-0.35	0.93	0.15	0.02	0.85	0.52	-0.34	0.34	-0.52
Common Stock Shares Outstanding	0.42	0.44	0.2	0.21	0.58	0.23	-0.1	-0.16	0.41	0.32	0.15	0.06	0.62		0.09	0.3	0.49	0.12	0.78	0.21	0.52	0.55	0.96	-0.9	0.86	0.07
Non Current Liabilities Total	0.77	0.67	0.72	0.75	0.58	0.56	0.56	-0.44	0.65	0.35	0.93	-0.57	-0.41	0.09		-0.15	0.72	0.95	-0.16	0.15	0.6	-0.61	0.2	-0.28	0.35	0.91
Other Current Assets	-0.17	0.11	-0.16	-0.21	-0.17	-0.15	-0.06	0.04	-0.29	-0.16	-0.24	0.07	0.15	0.3	-0.15		-0.14	-0.14	0.19	-0.33	-0.32	0.43	0.2	-0.09	0.02	-0.26
Other Stockholder Equity	0.67	0.54	0.73	0.78	0.62	0.88	0.24	-0.77	0.7	0.55	0.79	-0.09	-0.08	0.49	0.72	-0.14		0.75	0.13	-0.02	0.58	-0.4	0.58	-0.63	0.64	0.69
Total Liab	0.8	0.68	0.83	0.86	0.6	0.6	0.32	-0.49	0.63	0.48	0.93	-0.57	-0.35	0.12	0.95	-0.14	0.75		-0.08	0.18	0.57	-0.6	0.28	-0.31	0.4	0.88
Total Current Assets	0.24	0.23	0.09	0.04	0.41	-0.16	-0.46	0.19	0.14	0.44	-0.16	0.03	0.93	0.78	-0.16	0.19	0.13	-0.08		0.31	0.3	0.77	0.73	-0.55	0.58	-0.24
Short Term Debt	0.39	0.32	0.02	0.0	0.46	-0.37	-0.13	0.47	0.27	-0.02	0.24	-0.59	0.15	0.21	0.15	-0.33	-0.02	0.18	0.31		0.53	0.1	0.24	-0.41	0.49	0.29
Net Receivables	0.86	0.56	0.46	0.55	0.9	0.26	0.23	-0.06	0.9	0.4	0.7	-0.47	0.02	0.52	0.6	-0.32	0.58	0.57	0.3	0.53		-0.14	0.63	-0.69	0.77	0.71
Short Term Investments	-0.27	-0.13	-0.45	-0.49	-0.06	-0.52	-0.38	0.48	-0.33	-0.09	-0.65	0.24	0.85	0.55	-0.61	0.43	-0.4	-0.6	0.77	0.1	-0.14		0.4	-0.25	0.2	-0.68
Common Stock	0.58	0.5	0.34	0.37	0.69	0.32	-0.15	-0.24	0.52	0.45	0.29	-0.04	0.52	0.96	0.2	0.2	0.58	0.28	0.73	0.24	0.63	0.4		-0.9	0.89	0.22
Current Deferred Revenue	-0.54	-0.5	-0.33	-0.37	-0.66	-0.36	-0.05	0.25	-0.56	-0.23	-0.4	0.11	-0.34	-0.9	-0.28	-0.09	-0.63	-0.31	-0.55	-0.41	-0.69	-0.25	-0.9		-0.96	-0.34
Inventory	0.67	0.48	0.41	0.48	0.78	0.31	-0.06	-0.16	0.66	0.4	0.5	-0.24	0.34	0.86	0.35	0.02	0.64	0.4	0.58	0.49	0.77	0.2	0.89	-0.96		0.44
Good Will	0.85	0.54	0.58	0.73	0.72	0.49	0.41	-0.31	0.8	0.35	0.98	-0.66	-0.52	0.07	0.91	-0.26	0.69	0.88	-0.24	0.29	0.71	-0.68	0.22	-0.34	0.44

Click cells to compare fundamentals

Myriad Genetics Account Relationship Matchups

Myriad Genetics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.6B	1.4B	1.3B	1.2B	1.1B	670.7M
Other Current Liab	82.3M	104.9M	122.9M	60.1M	109.3M	114.8M
Total Current Liabilities	117.8M	145.9M	204.3M	137.2M	155.9M	163.7M
Total Stockholder Equity	1.1B	881M	967.8M	885.8M	783.2M	529.5M
Property Plant And Equipment Net	57.3M	100.4M	125.3M	187.3M	180.6M	189.6M
Net Debt	140.3M	(117M)	(166.1M)	88.1M	20M	21M
Retained Earnings	25.6M	(227M)	(254.2M)	(366.2M)	(629.5M)	(598.0M)
Accounts Payable	33.3M	20.5M	29.6M	28.8M	25.8M	17.0M
Cash	93.2M	117M	258.4M	56.9M	132.1M	92.1M
Non Current Assets Total	1.2B	1.0B	835.9M	924.1M	832.9M	874.5M
Common Stock Shares Outstanding	76M	74.8M	78M	80.6M	82.8M	75.0M
Non Current Liabilities Total	356M	224.8M	148.6M	175.7M	207.4M	217.8M
Other Current Assets	46.4M	122.1M	38.4M	20.4M	36.4M	55.5M
Other Stockholder Equity	1.1B	1.1B	1.2B	1.3B	1.4B	1.5B
Total Liab	473.8M	537.8M	352.9M	312.9M	363.3M	381.5M
Total Current Assets	348.6M	389.4M	484.8M	274.6M	313.6M	306.6M
Net Receivables	138.6M	89.5M	91.3M	101.6M	114.3M	61.5M
Short Term Investments	43.7M	33.7M	81.4M	58M	8.8M	8.4M
Inventory	31.4M	27.1M	15.3M	20.1M	22M	23.1M
Good Will	417.2M	329.2M	239.2M	286.8M	287.4M	245.9M
Intangible Assets	684.7M	578.8M	404.1M	379.7M	349.5M	339.7M

Pair Trading with Myriad Genetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.

Moving against Myriad Stock

0.91	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.85	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.83	GILD	Gilead Sciences	Pair Corr
0.76	VTRS	Viatris	Pair Corr
0.71	EWTX	Edgewise Therapeutics	Pair Corr

The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.

The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:

How To Invest In Myriad

Details

Is Myriad Stock a good investment?

Details

What is Myriad Genetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.28)

Revenue Per Share

9.205

Quarterly Revenue Growth

0.112

Return On Assets

(0.05)

Return On Equity

(0.16)

The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Myriad Total Revenue vs Current Deferred Revenue Analysis

Total Revenue vs Current Deferred Revenue

Total Revenue vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Total Revenue

Current Deferred Revenue

Myriad Genetics fundamental ratios Correlations

Myriad Genetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Myriad Genetics fundamental ratios Accounts

Pair Trading with Myriad Genetics

Moving against Myriad Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 0.98	Non Current Assets Total
Common Stock	+ 0.96	Common Stock Shares Outstanding
Total Liab	+ 0.95	Non Current Liabilities Total
Total Stockholder Equity	+ 0.94	Total Assets
Non Current Liabilities Total	+ 0.93	Non Current Assets Total
Total Liab	+ 0.93	Non Current Assets Total

Inventory	- 0.96	Current Deferred Revenue
Retained Earnings	- 0.94	Property Plant And Equipment Net
Current Deferred Revenue	- 0.9	Common Stock
Current Deferred Revenue	- 0.9	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.77	Retained Earnings
Current Deferred Revenue	- 0.69	Net Receivables